In long term analyses of two clinical responding patients the ratio of Kyn/Trp remained stable.
Introduction
Lung cancer is one of the leading causes of cancer deaths in both men and women worldwide, with NSCLC accounting up to 85% of the cases (1) (4, 5) . These data supports the idea that checkpoint blockade can enhance polyfunctional spontaneous pre-existing T cell responses. We have formerly shown spontaneous cytotoxic T cell reactivity against indoleamine 2.3 dioxygenase (IDO) (6, 7) an immune regulatory enzyme that suppresses T-cell immunity. IDO catalyzes the initial and ratelimiting step in the degradation of tryptophan (Trp), which leads to local depletion of Trp and an increase in downstream metabolites e.g. kynurenine (Kyn) . It has been demonstrated that patients with different tumour types have elevated Kyn/Trp ratio compared to healthy donors (HD), which suggests elevated IDO activity in cancer patients (8) . Moreover, the ratio of Kyn/Trp in serum has been proposed by others as a non-invasive, in vivo biomarker for evaluating the efficacy of IDO Author Manuscript Published OnlineFirst on November 11, 2013; DOI: 10.1158/1078-0432.CCR- inhibitors in the clinic (9) . Clinical investigation of IDO inhibition in phase I dose-escalating trials has been initiated for patients with metastatic solid tumours (10, 11) .
It is well-known that cancer cells as well as dendritic cells may upregulate IDO. As IDO-specific CD8 T cells has been shown to boost immunity against tumor associated antigens by eliminating IDO + regulatory cells, which, in turn, has lead to a decrease in regulatory T cells (Tregs) (7) this justified clinical testing of the safety and efficacy of IDO-targeting vaccination. Thus, we performed a phase I vaccination study in patients with stage III/IV NSCLC testing an IDO-derived peptide vaccine applied in Montanide adjuvant.
Material and Methods

Patients
Patients were enrolled at the Department of Oncology at Copenhagen University Hospital, Herlev, Denmark from June 2010 to May 2012. All patients provided written informed consent prior to inclusion and GCP monitoring of the study was conducted. The study was performed in accordance with the Helsinki II declaration and was initiated after approval from the National Board of Health and the local Ethics Committee at the Capital Region of Denmark. The study was registered at www.clinicaltrials.gov (NCT01219348). Primary end point was toxicity. In addition, clinical benefit and immunity were assessed. Tumour staging was performed according to the Union for International Cancer Control (UICC) classification on CT scans according to RECIST version 1.1.
Clinical assessment by CT scans was performed at baseline and subsequently every 3 rd month. Anti- 
Flow cytometry
Flow cytometry analyses were carried out on a FACS Canto II cytometer (BD) Biosciences.
Peripheral blood mononuclear cells (PBMC) were obtained from peripheral blood by gradient centrifugation by Lymphoprep technique. Isolated cells were frozen immediately with 10% DMSO and 90% humanised AB-serum and stored at -140º Celsius.
For the CD4+/Treg assay PBMCs were thawed and incubated with mouse serum (Invitrogen) followed by labelling with fluorchrome-conjugated antibodies: PB-CD3 (DAKO), PerCP-CD4 (BD Bioscience), APC-CD25 (BD-Pharmingen), PE-CD27 (BD-Pharmingen) and the relevant isotypes were used for antigen surface staining. PE-FoxP3 (ebioscience) and PE-isotype PE rat IgG2a (ebioscience) were used for intracellular staining; cells were fixed and permeabilized using a fixation/permeabilization kit (ebioscience) according to the manufacturer´s instruction. As dead cell marker APC-Cy7 near IR (Invitrogen) fluorescent reactive dye was used. Antigen surface staining for CD8+/CD4+ Tcm, Tem, Temra and Tnaïve analyses were PB-CD3 (DAKO), PerCP-CD4 (BD Bioscience), APC-CD8 (BD Pharmingen), PE-Cy7-CCR7 (BD Pharmingen), Krom-Orange-CD45 (Ramcon), FITC-CD45RA (BD Bioscience). For analyses of myeloid-derived suppressor cells (MDSC) surface antigen labelling was used: FITC-HLA-DR-lineage negative (BD Pharmingen), PE-Cy7-CD3 lineage (BD Pharmingen), PE-Cy7-CD19 lineage (BD Pharmingen) and PE-Cy7-CD56 lineage (BD Pharmingen), PE-CD33 (DAKO), APC-CD11b (BD Pharmingen), PerCP-CD14 (BD Pharmingen) and PB-CD15 (Biolegend).
Research. Tetramer staining was performed in PBS +2% FCS for 15 minutes at 37°C, followed by antibody staining for 30 minutes on ice. The tetramers were prepared using the MHC-peptide exchange 
Cytotoxicity assay
Conventional
51 Cr-release assays for CTL-mediated cytotoxicity were carried out as described (13) . 
Establishment of IDO specific T-cell cultures
The culture was enriched for specific cells by staining PBMC with HLA-A2/IDO5-PE and HLA-A2/IDO5-APC tetramer followed by sorting of tetramer-binding cells on a FACS Aria. Specific cells were expanded by incubation with 0.6 µg anti-CD3 (eBioscience, clone OKT3) and high dose (6000 U/ml for at least 14 days) IL-2 (Proleukin, Novartis).
Assessment of IDO activity in patient serum
Sera from patients were obtained at pre-treatment, at the 4 th , at the 6 th vaccine and subsequently every 3 rd month. Nine ml of blood were drawn in a dry vial and spun down at 3000 rpm in 10 minutes. Sera were aliquoted in 1.8 ml Nunc cryo-preservation vials and stored at -80° Celsius freezer.
Research. IDO activity was estimated by quantifying tryptophan (Trp) and its metabolite kynurenin (Kyn) in patient sera, essentially as previously described (15, 16) . Briefly, 100 µL thawed serum were diluted 1:2 with 0.05M KOP 4 buffer PH 6.0, followed by protein precipitation with TCA 2M. Trp and Kyn were then identified in 100 µL supernatant by high-performance liquid chromatography (HPLC) (LC 10 AvP system, Shimadzu, Duisberg, Germany) using a C18 column (ReproSil-Pur Basic versus progressive disease (PD) patients an unpaired t-test was applied. In all analyses a two-sided P value of <0.05 was considered to be significant.
Results
Demographics
Patients characteristics for both HLA-A2 positive patients (N=15) and HLA-A2 negative patients (N=10) otherwise eligible but not harbouring the necessary HLA-A2 allele for vaccination are presented in Fig.1A . According to protocol requirements CT scans for HLA-A2 positive patients was described using RECIST 1.1 whereas for HLA-A2 negative patients RECIST 1.0 according to local standard was used thus baseline characteristics were not completely comparable among the two groups. Patients were in SD after chemotherapy and/or TKI treatment (any line) at time of enrolment. Vaccine treatment was initiated at least 28 days after last dose of chemotherapy. 
Toxicity
No grade 3-4 CTCAE toxicity was observed hence the CTCAE 1-2 events are shown in Fig.1C .
High frequencies of fatigue, shortness of breath, coughing and haemoptysis were present at baseline and were probably related to the lung cancer. Nausea and headache were observed in relation to the development of brain metastases, while dyspepsia, abdominal pain and diarrhoea could be related to the vaccine treatment, as IDO is expressed in the epithelial cells in the gastrointestinal tract (17, 18) .
In 90% of the patients development of grade 1-2, short term, local reactions at the vaccine site (i.e. 
Frequency of IDO-specific T cells in PBMC during vaccination
Presence of IDO specific CD8+ T cells was demonstrated by IFNy Elispot. All assays were performed in duplicates at two different cell numbers (2.5*10e5 and 6.0*10e5 PBMCs/well). In 
Stabilization of Kyn/Trp ratio suggesting IDO blockade
Research. Criteria (irRC) (23) . In our study the median OS was >2 years, which was higher than expected for this patient group and is emphasized by the fact that 6/7 of the SD patients are still alive. One explanation could be that T-cell priming by the IDO vaccine in some patients is of importance for response to succeeding anti-neoplastic treatments or induces long lasting anti-tumour effects (24) .
To this end, the recently FDA approved sipuleucel T vaccine for advanced prostate cancer patients demonstrated prolonged overall survival though no effect on time to progression was demonstrated (25).
The clinical significance of HLA phenotype in cancer patients has been widely investigated.
Importantly, it was recently described in a large study that expression of HLA-A2 was an unfavourable prognostic factor in stage I NSCLC patients (26). This study underlines the potential importance of the significantly longer OS observed in vaccinated HLA-A2 patients compared to unvaccinated HLA-A2 negative NSCLC patients, though these data need confirmation in large clinical trials. To this end, it is important to stress that the difference in OS among the two groups observation indicates that IDO could be a suitable target for vaccination as immunity towards IDO seems to be a general characteristic of NSCLC patients independent of clinical status. In 2 SD patients an IDO-specific Elispot response was detected during 1 year of treatment, suggesting sustained long-term IDO reactivity. Noteworthy, we found a trend towards higher pre-treatment levels of IDO specific T cells in the SD+PR patients compared to the PD patients. Thus, our data indicate that the SD+PR patients had a higher level of T cells primed for an IDO response, which is in accordance with previously suggested IDO immunity (7) . In addition, we utilized the MHC peptide tetramer technology to directly visualize IDO-specific T cells. 
sensitive for IFNy response elevated Kyn/Trp ratio may also reflect unspecific inflammation (38) .
The presence of an "inflamed" microenvironment might be used to consider patients as candidates for immunotherapy likewise the expression of PD-L1, IDO or presence of Tregs might necessitate agents targeting negative regulation (39) . We found 8/11 patients demonstrating stable or lower level of IDO activity after the 6 th vaccine. The SD+PR patients had a trend toward a higher rate of IDO specific T cells and higher Kyn/Trp ratio prior to treatment. Taken together, this point towards a higher pre-vaccination IDO activity in the SD+PR patients compared to the PD patients.
Interestingly, in two patients with long-lasting clinical response stable Kyn/Trp ratio was maintained at long term pointing towards a possible role as marker of response.
Overall, regarding the induced Treg decrease, the possibly NK cell increase, the demonstration of 
Supplementary figures: FACS plots
Research. ------------------------------------------- 
----------------------------------------------PR
Months
